Biotechnology
Filter News
Found 21,804 articles
-
OncoQuest Announces Presentation of Translational Immunology Data from Phase II Clinical Study Examining Oregovomab
11/8/2017
The findings presented were drawn from the 81 patients in the trial from the Italian investigative centers.
-
Syndax to Present at the SITC 32nd Annual Scientific Meeting
11/8/2017
Syndax today announced five presentations at the upcoming SITC 32nd Annual Meeting being held November 8-12, 2017 in National Harbor, Maryland.
-
Biognosys Announces a Technological Breakthrough in the Development of Its Next-Generation Proteomics Workflow
11/8/2017
Biognosys announced today a breakthrough in the development of its next generation proteomics technology that helps scientists to understand complex biological processes.
-
Viking Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update
11/8/2017
Research and development expenses for the three months ended September 30, 2017 were $3.5 million compared to $2.1 million for the same period in 2016.
-
FDA Approves Genentech's Zelboraf, the First-Ever Drug to Treat Specific Rare Blood Disease
11/7/2017
People diagnosed with the rare blood disorder known as Erdheim-Chester disease have a new treatment option. -
Shares of Haemonetics are up nearly 10 percent this morning after the company announced it was cutting about 11 percent of its workforce in a restructuring effort.
-
Salaries and total compensation can range from $300,000 to $500,000 per year for these employees – whether they have a Ph.D. or are just out of college.
-
Progenity snagged $125M in funding that will allow the company to accelerate development of its gastrointestinal platform.
-
Bristol-Myers is initiating a Phase III clinical trial of BMS-986205 with nivolumab in patients with advanced melanoma.
-
Puma received gross proceeds of $50 million from the first tranche of the credit facility upon closing on Oct. 31.
-
Phase III data showed Alecensa extended the average time that people lived without their disease worsening compared to crizotinib.
-
U.S. FDA Approves Keryx Biopharma's Auryxia (ferric citrate) Tablets as a Treatment for People with Iron Deficiency Anemia and Chronic Kidney Disease, Not on Dialysis
11/7/2017
Auryxia is the only oral treatment option available today developed and approved specifically for adults living with iron deficiency anemia and chronic kidney disease, not on dialysis.
-
Batu Biologics Receives FDA Clearance for First Multi-Pronged Immunotherapy Targeting the Blood Vessels That Feed Cancer
11/7/2017
Batu Biologics, an immuno-oncology company dedicated to the development of its tumor-angiogenesis targeting immune therapy, ValloVax™, has received an Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) allowing Batu to proceed with Phase 1 clinical trials.
-
Sarepta Therapeutics Announces FDA Clearance of IND for the Company’s PPMO Exon 51 Candidate, SRP-5051
11/7/2017
Sarepta to immediately initiate a Phase 1/2a clinical trial in patients with Duchenne muscular dystrophy (DMD) amenable to skipping exon 51.
-
Orphazyme Receives Orphan Drug Designation To Arimoclomol for Inclusion Body Myositis From the FDA
11/7/2017
As described in the offering circular published by Orphazyme A/S on 6 November 2017, the Company applied to the FDA for the designation in September 2017.
-
TriNetX Achieves ISO 27001:2013 Certification
11/7/2017
The certification reinforces TriNetX's dedication to conducting best practices and its determination to provide the highest level of information security for its clients.
-
Novan Announces Plan to Complete Development of SB204 Acne Candidate via Third Party Funding and Execution
11/7/2017
Under the proposed transaction, a new entity established by the third party would provide both the necessary capital to fund and the clinical expertise to execute an additional Phase 3 pivotal trial for SB204.
-
Genocea Presents New Data Demonstrating the Power and Versatility of Its ATLAS Antigen Identification Platform at SITC 2017
11/7/2017
ATLAS continues to demonstrate superiority to in silico methods of neoantigen identification in multiple tumor types.
-
OrthoTrophix Presents the Key Data of the TPX-100 Phase II Study as a Late Breaking Abstract at American College of Rheumatology Annual Meeting
11/7/2017
Based on this double-blinded, placebo-controlled, multi-center study, data are presented from 93 subjects with bilateral knee OA who received 4 weekly doses of TPX-100 by intra-articular administration in one knee and identical placebo injections in the other, with at least one follow-up evaluation at 6 and 12 months.
-
ObsEva SA Announces the Completion of Patient Recruitment in the EDELWEISS Phase IIb Clinical Trial of OBE2109 for the Treatment of Endometriosis
11/7/2017
Approximately 330 patients are expected to be randomized in the EDELWEISS clinical trial, and primary endpoint efficacy results continue to be anticipated in mid-2018.